Gavi's impact

In December 2021, the Gavi Board made history by approving funding to support the roll-out of the world’s first malaria vaccine – nearly 35 years in development – in sub-Saharan Africa in 2022–2025. According to the World Health Organization (WHO), the vaccine is estimated to save 1 life for every 200 children vaccinated.

Consistent funding and investment are crucial to ensure this new, vital tool reaches equally all those who need it. As long as resources are available, Gavi pledges its continued commitment and support to the fight against one of Africa’s deadliest diseases.

The issue

Children aged under five years are at the greatest risk of dying from malaria and account for more than 75% of the global deaths from the disease. Unlike adults, young children have not had the opportunity to develop partial immunity through years of exposure, making them particularly at risk.

In 2023 alone, malaria caused 597,000 deaths globally, and 432,000 child deaths in Africa – highlighting the urgent need to protect our youngest and most vulnerable. The African region shoulders the heaviest malaria burden globally, accounting for about 94% of all cases and 95% of deaths, according to WHO data.

Gavi's response

Malaria vaccines

As of October 2025, over 39 million doses have been delivered to 25 endemic countries in Africa which have introduced malaria vaccines into routine immunisation with Gavi support:

  • 7 countries have introduced the vaccine in 2025: Burundi, Uganda, Mali, Guinea, Togo, Ethiopia and Zambia; and 1 more country (Guinea-Bissau) plans to roll out the vaccine in 2025.
  • 14 countries introduced the vaccine in 2024: Cameroon, Burkina Faso, Sierra Leone, Benin, Liberia, Côte d’Ivoire, South Sudan, Mozambique, Central African Republic, Niger, Chad, Democratic Republic of the Congo, Sudan and Nigeria.
  • 3 countries – Ghana, Kenya and Malawi – introduced the first malaria vaccine, RTS,S, in 2019 during the Malaria Vaccine Implementation Programme (MVIP), co-funded by Gavi, the Global Fund to Fight AIDS, Tuberculosis and Malaria and UNITAID. Since 2024, these countries have been funded under Gavi’s Malaria Vaccine Programme, aligning them with the other countries that have introduced malaria vaccines.

Malaria vaccine safety and effectiveness: Both the RTS,S/AS01 and R21/Matrix-M vaccines are prequalified and recommended by WHO to prevent malaria in children and are safe and effective.

  • In phase 3 clinical trials, both vaccines reduced malaria cases by more than half during the first year after vaccination, a period when children are at high risk of illness and death. A fourth dose given in the second year of life prolonged protection.
  • Both vaccines reduce malaria cases by 75% when given seasonally in areas of highly seasonal transmission.
  • The vaccines target P. falciparum, the deadliest malaria parasite globally and the most prevalent in Africa. More about the vaccine here: https://www.who.int/news-room/questions-and-answers/item/q-a-on-rts-s-malaria-vaccinee

Useful information and resources:

Read on VaccinesWork

How to apply for vaccine support

Gavi support guidelines

Latest articles about malaria

Genetically modified mosquitoes and malaria in Africa: top scientist shares latest advances

Mosquitoes can be genetically modified to help reduce the number of malaria-carrying mosquitoes, and therefore malaria transmission.

Mosquitoes use gut bacteria to fight the malaria they transmit – scientists are exploring how to use this to end the disease

In a sense, a malaria-transmitting mosquito is a sick mosquito. This is where bacteria can help.

In Mozambique's Zambezia province, mothers go the extra mile to get kids protected with malaria vaccines

Mozambique introduced the malaria vaccine in its worst-hit province on 5 August 2024. Charles Mangwiro reports.

How effective are malaria vaccines?

When it comes to measuring efficacy, where, when and how you give malaria vaccines matters.

Bangladesh is gunning for zero malaria deaths by 2027

Both cases and fatalities are in decline. But are the current deadlines feasible? Mohammad Al Amin reports. 

How will Cote d'Ivoire roll out the malaria vaccine?

Yesterday, Côte d'Ivoire made history by becoming the first country to introduce the R21 malaria vaccine into its routine immunisation programme. We spoke to the country's EPI Director to find out how they plan to roll out this lifesaver.

Battling malaria, South Sudan anticipates roll-out of life-saving vaccines

As South Sudan prepares to deploy a new weapon in its fight against malaria, the R21 vaccine, Winnie Cirino surveys the parasitic disease’s foothold. 

Here’s how reducing malaria can add $16 billion to Africa’s GDP every year

Meeting global targets to reduce malaria by 90% by 2030 will not only save thousands of lives, but also add $126 billion to Africa’s GDP. 

Malaria bites: health workers in 80 countries share their experiences

As two malaria vaccines begins to roll out in many countries, health workers reflect on their experiences of the parasitic killer. 

In Benin, the disappearance of mangroves is threatening human health

Mangroves mitigate the effects of floods and tidal waves, and also aid in curbing vector-borne diseases like malaria. They’re also vanishing.

Climate change causes malaria cases to triple in northwest Pakistan

In the wake of 2022’s floods, provincial health leaders say they need a new “climate-change specific” plan.

Fighting malaria with digital health: How Kenya is transforming its community health sector

The electronic Community Health Information System (eCHIS) sends diagnostic data directly from households to facilities, enabling timely malaria treatment.

Last updated: 30 Oct 2025